Our CEO, Birgit Zech, and our CSO, Edward Holson, will attend BIO–Europe 2024 in Stockholm, Sweden, from November 4 to 6. At this leading life science partnering event, Birgit and Ed will engage with key stakeholders in the healthcare industry and discuss Anavo's progress in advancing the IGNITE platform for developing first-in-class phosphatase modulators. To learn more about Anavo's approach, connect with Birgit and Ed through the event's partnering system. #BIOEurope #BIOEurope24
Anavo Therapeutics BV
Biotechnologisch onderzoek
Leiden, South Holland 1.337 volgers
Unlocking the Phosphatase Target Class
Over ons
Anavo Therapeutics is the first company to systematically drug phosphatases, a rich target space previously considered undruggable for decades. We have attracted world-leading scientific expertise in phosphatase-driven disease biology and drug discovery to unlock the full potential of phosphatase-targeted allosteric modulators. In oncology, Anavo is developing multiple first-in-class therapeutic programs and will build on partnerships around its platform to establish a rich pipeline across several indications. Anavo is backed by blue-chip investors M Ventures, INKEF Capital, Taiho Ventures, and Bioqube Ventures.
- Website
-
http://www.anavotx.com
Externe link voor Anavo Therapeutics BV
- Branche
- Biotechnologisch onderzoek
- Bedrijfsgrootte
- 2-10 medewerkers
- Hoofdkantoor
- Leiden, South Holland
- Type
- Particuliere onderneming
- Specialismen
- drug discovery, phospatase biology en oncology
Locaties
-
Primair
Routebeschrijving
J.H. Oortweg 19
Leiden, South Holland 2333 CH, NL
Medewerkers van Anavo Therapeutics BV
Updates
-
Today, we welcome Edward Holson, Ph.D., as Chief Scientific Officer. Dr. Holson brings over 25 years of expertise in medicinal chemistry, drug discovery, and novel therapeutic development. In this role, he will guide Anavo’s scientific strategy, focusing on the advancement of our proprietary IGNITE platform and development of first-in-class phosphatase modulators. Based in Boston, Dr. Holson will also serve as President of Anavo US, overseeing R&D operations in both the US and Europe. This dual presence will enable us to leverage the complementary strengths of our research teams across these leading biotechnology regions. With his leadership and expertise in small-molecule therapies, we are excited to expand our research and development efforts on both sides of the Atlantic. For more information on the announcement, check out this link: https://lnkd.in/d6vFzYch #Biotech #DrugDiscovery #Innovation
-
-
Join us at the American Association for Cancer Research Annual Meeting in San Diego! Our CSO, Dr. Shaun McNulty, and our Head of Non-Clinical Development, Dr. Martin J. Woodward are looking forward to connecting with industry partners and the scientific community to discuss the potential of unlocking phosphatases as a novel target class for #cancer treatment and sharing our vision for accessing a space that was previously considered undruggable. Interested in learning more about our approach? Visit www.anavotx.com
-